Morgan Stanley Sees Range of Risk Factors for Aflac

In a report published Tuesday, Morgan Stanley analyst Nigel Dally reiterated an Equal-Weight rating on

. In the report, Morgan Stanley noted, “ We remain Equal-weight on Aflac following its Japan investor day, which had few surprises. While we consider the valuation to be relatively attractive, there are a range of risk factors that have the potential to weigh on the outlook, leading us to recommend investors presently stay on the sidelines.” Aflac closed on Monday at $59.84.